公开(公告)号：US20070003519A1

公开(公告)日：2007-01-04

申请号：US10551667

申请日：2004-04-01

Applicant: Patrick Lu ,  Frank Xie ,  Martin Woodle ,  Yijin Liu ,  Quinn Tang ,  Jun Xu

Inventor： Patrick Lu ,  Frank Xie ,  Martin Woodle ,  Yijin Liu ,  Quinn Tang ,  Jun Xu

IPC: A61K48/00

CPC classification number: C12Q1/6886 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/4748 ,  C07K14/475 ,  C07K14/71 ,  C07K16/30 ,  C12N15/111 ,  C12N15/1135 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/12 ,  C12Q2600/112 ,  G01N33/57407 ,  G01N2500/00

Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.

Abstract translation: 本发明涉及通过分别通过上调，沉默和/或下调基因如EGFR-RP，TRA1，MFGE8，TNFSF13和ZFP236来操纵靶基因表达来治疗癌症的方法。 该方法可用于通过增强作为靶标的基因（例如ICT1030）的蛋白质，肽药物和基因治疗方式的表达来治疗癌症和/或抑制肿瘤生长; 或通过RNA干扰来沉默和/或下调诸如针对抗体，小分子和其他抑制剂药物形态验证的ICT1024，ICT1025和ICT1031和ICB1003的靶标。